Metronomic chemotherapy in the Hematology patient as a non-curative alternative, at the Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera” from January 2016 to December 2019.
Revista Ciencia y Salud / eISSN: 2215-4949 / https://revistacienciaysalud.ac.cr/ojs

Vol. 8 No. 2 (2024)Artículos

Vol. 8 No. 2 (2024)

Metronomic chemotherapy in the Hematology patient as a non-curative alternative, at the Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera” from January 2016 to December 2019.

Artículos

Supplementary Files

PDF (Español (España))

Keywords

Administration metronomic
pediatrics
palliative care
drug therapy

How to Cite

Valverde Muñoz, K., Chacón Hernández, G., Gutiérrez Valverde, D., Rodríguez Rodríguez , J., & Granados Alfaro, P. (2024). Metronomic chemotherapy in the Hematology patient as a non-curative alternative, at the Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera” from January 2016 to December 2019. Revista Ciencia Y Salud, 8(2), 125–132. https://doi.org/10.34192/cienciaysalud.v8i2.788

Abstract

Introduction: Metronomic Chemotherapy consists of the administration of chemotherapy at low doses and in intervals with minimal side effects. Used in advanced cancer, to keep the neoplastic disease stable and offer a life quality improvement in these patients, together with palliative support care.

Methodology: A retrospective observational study, covering a 3-year period, from January 2016 to December 2019, characterizing patients with hematological disease who use metronomic chemotherapy as a non-curative option at the National Children's Hospital “Dr. Carlos Sáenz Herrera.”

Results: Within a total of 52 patients, the predominant gender was male with a 75.0% (n=39). Regarding the rate of incidence according to province, the province of Limón had the highest incidence with 6.9 x 100 000 inhabitants under 13 years of age, followed by San José with 6.4 x 100 000 inhabitants under 13 years of age and Guanacaste with 6.2 x 100 000 inhabitants under the age of 13. The symptoms during the treatment were predominantly joint pain in 35.2% followed by inappetence in 21.1%, fatigue in 13% and bleeding in 7.7%. 92.3% of the patients died before the 3-year duration of the Metronomic guide; 5.8% had a stable disease. A 72.3% of the patients died at home, only 27.6% (n=13) in the hospital.

Conclusion: The metronomic chemotherapy regime is reported as well tolerated by patients, with an evident a positive trend for patients who have exhausted the current therapeutic possibilities; including a multidisciplinary approach is done with the palliative care team.

https://doi.org/10.34192/cienciaysalud.v8i2.788
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Kathia Valverde Muñoz, Gabriela Chacón Hernández, Daniela Gutiérrez Valverde, Jorge Rodríguez Rodríguez , Paola Granados Alfaro

Downloads

Download data is not yet available.